Invesco Ltd. Has $153.58 Million Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)

Invesco Ltd. boosted its holdings in shares of QuidelOrtho Co. (NASDAQ:QDEL - Free Report) by 71.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,447,446 shares of the company's stock after acquiring an additional 1,439,293 shares during the quarter. Invesco Ltd. owned 5.13% of QuidelOrtho worth $153,584,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Blue Trust Inc. lifted its position in shares of QuidelOrtho by 188.0% in the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company's stock worth $58,000 after buying an additional 844 shares during the last quarter. Spire Wealth Management bought a new stake in QuidelOrtho during the fourth quarter worth approximately $74,000. KBC Group NV grew its holdings in QuidelOrtho by 122.9% during the fourth quarter. KBC Group NV now owns 3,437 shares of the company's stock valued at $153,000 after purchasing an additional 1,895 shares during the last quarter. LPL Financial LLC bought a new position in shares of QuidelOrtho in the fourth quarter valued at approximately $221,000. Finally, Captrust Financial Advisors bought a new stake in shares of QuidelOrtho during the 3rd quarter worth $238,000. Institutional investors and hedge funds own 99.00% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. UBS Group upped their price target on shares of QuidelOrtho from $43.00 to $45.00 and gave the company a "neutral" rating in a report on Thursday, February 13th. StockNews.com downgraded QuidelOrtho from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Finally, Royal Bank of Canada lowered their price objective on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating on the stock in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, QuidelOrtho has an average rating of "Hold" and a consensus target price of $51.20.

QuidelOrtho Price Performance

NASDAQ QDEL traded down $0.10 during trading on Friday, reaching $25.17. 938,597 shares of the company traded hands, compared to its average volume of 989,274. QuidelOrtho Co. has a 1-year low of $24.44 and a 1-year high of $49.45. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -0.83 and a beta of 0.43. The stock's 50 day moving average price is $35.42 and its two-hundred day moving average price is $39.65. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%. As a group, analysts anticipate that QuidelOrtho Co. will post 2.3 EPS for the current year.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.